Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria

Matt Morgan, Andrew Cooke, Laura Rogers, Beverley Adams-Huet, David A. Khan

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Management of antihistamine refractory chronic idiopathic urticaria (CIU) has poorly defined therapeutic options. Objective: To evaluate the efficacy of dapsone (4,4'-diaminodiphenylsulfone) in antihistamine refractory CIU compared with placebo. Methods: Twenty-two patients with antihistamine refractory CIU were randomly assigned to 100 mg of dapsone daily or placebo for 6 weeks in a 14-week double-blind, placebo-controlled crossover trial. End points were measured from a daily diary that reflected the weekly hive score, the weekly itch score, and a visual analog scale (VAS) score. Secondary to a carryover effect, the first period results were analyzed as a parallel design that compared placebo with dapsone directly by using repeated-measures analysis. Results: After 6 weeks, the patients in the dapsone arm showed mean improvement over baseline in VAS (2.3 [95% CI, 0.6-4.1], P= .01), urticaria score (-3.5 [95% CI, -6.2 to -0.9], P= .01), and itch score (-4.8 [95% CI, -7.6 to -2.1], P= .001), whereas the placebo arm showed no improvement over baseline for VAS, urticaria, or itch scores. Dapsone showed greater improvement compared with placebo for itch (P= .047) and VAS (P= .04). Of the 22 patients, 3 showed complete resolution of hives and itch with dapsone, whereas 31% and 41% had ≥50% resolution of hives and itch, respectively. No serious adverse effects were observed with dapsone. Conclusion: To our knowledge, this is the first double-blind, placebo controlled study of dapsone in CIU and indicates that dapsone has efficacy in patients with antihistamine refractory CIU.

Original languageEnglish (US)
Pages (from-to)601-606
Number of pages6
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume2
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Dapsone
Histamine Antagonists
Urticaria
Placebos
Visual Analog Scale
Cross-Over Studies

Keywords

  • Antihistamine
  • Chronic idiopathic urticaria
  • Dapsone
  • RCT
  • Urticaria

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria. / Morgan, Matt; Cooke, Andrew; Rogers, Laura; Adams-Huet, Beverley; Khan, David A.

In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 2, No. 5, 2014, p. 601-606.

Research output: Contribution to journalArticle

@article{91c2633e45a847dcb3ffc32e51c7bca7,
title = "Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria",
abstract = "Background: Management of antihistamine refractory chronic idiopathic urticaria (CIU) has poorly defined therapeutic options. Objective: To evaluate the efficacy of dapsone (4,4'-diaminodiphenylsulfone) in antihistamine refractory CIU compared with placebo. Methods: Twenty-two patients with antihistamine refractory CIU were randomly assigned to 100 mg of dapsone daily or placebo for 6 weeks in a 14-week double-blind, placebo-controlled crossover trial. End points were measured from a daily diary that reflected the weekly hive score, the weekly itch score, and a visual analog scale (VAS) score. Secondary to a carryover effect, the first period results were analyzed as a parallel design that compared placebo with dapsone directly by using repeated-measures analysis. Results: After 6 weeks, the patients in the dapsone arm showed mean improvement over baseline in VAS (2.3 [95{\%} CI, 0.6-4.1], P= .01), urticaria score (-3.5 [95{\%} CI, -6.2 to -0.9], P= .01), and itch score (-4.8 [95{\%} CI, -7.6 to -2.1], P= .001), whereas the placebo arm showed no improvement over baseline for VAS, urticaria, or itch scores. Dapsone showed greater improvement compared with placebo for itch (P= .047) and VAS (P= .04). Of the 22 patients, 3 showed complete resolution of hives and itch with dapsone, whereas 31{\%} and 41{\%} had ≥50{\%} resolution of hives and itch, respectively. No serious adverse effects were observed with dapsone. Conclusion: To our knowledge, this is the first double-blind, placebo controlled study of dapsone in CIU and indicates that dapsone has efficacy in patients with antihistamine refractory CIU.",
keywords = "Antihistamine, Chronic idiopathic urticaria, Dapsone, RCT, Urticaria",
author = "Matt Morgan and Andrew Cooke and Laura Rogers and Beverley Adams-Huet and Khan, {David A.}",
year = "2014",
doi = "10.1016/j.jaip.2014.06.004",
language = "English (US)",
volume = "2",
pages = "601--606",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria

AU - Morgan, Matt

AU - Cooke, Andrew

AU - Rogers, Laura

AU - Adams-Huet, Beverley

AU - Khan, David A.

PY - 2014

Y1 - 2014

N2 - Background: Management of antihistamine refractory chronic idiopathic urticaria (CIU) has poorly defined therapeutic options. Objective: To evaluate the efficacy of dapsone (4,4'-diaminodiphenylsulfone) in antihistamine refractory CIU compared with placebo. Methods: Twenty-two patients with antihistamine refractory CIU were randomly assigned to 100 mg of dapsone daily or placebo for 6 weeks in a 14-week double-blind, placebo-controlled crossover trial. End points were measured from a daily diary that reflected the weekly hive score, the weekly itch score, and a visual analog scale (VAS) score. Secondary to a carryover effect, the first period results were analyzed as a parallel design that compared placebo with dapsone directly by using repeated-measures analysis. Results: After 6 weeks, the patients in the dapsone arm showed mean improvement over baseline in VAS (2.3 [95% CI, 0.6-4.1], P= .01), urticaria score (-3.5 [95% CI, -6.2 to -0.9], P= .01), and itch score (-4.8 [95% CI, -7.6 to -2.1], P= .001), whereas the placebo arm showed no improvement over baseline for VAS, urticaria, or itch scores. Dapsone showed greater improvement compared with placebo for itch (P= .047) and VAS (P= .04). Of the 22 patients, 3 showed complete resolution of hives and itch with dapsone, whereas 31% and 41% had ≥50% resolution of hives and itch, respectively. No serious adverse effects were observed with dapsone. Conclusion: To our knowledge, this is the first double-blind, placebo controlled study of dapsone in CIU and indicates that dapsone has efficacy in patients with antihistamine refractory CIU.

AB - Background: Management of antihistamine refractory chronic idiopathic urticaria (CIU) has poorly defined therapeutic options. Objective: To evaluate the efficacy of dapsone (4,4'-diaminodiphenylsulfone) in antihistamine refractory CIU compared with placebo. Methods: Twenty-two patients with antihistamine refractory CIU were randomly assigned to 100 mg of dapsone daily or placebo for 6 weeks in a 14-week double-blind, placebo-controlled crossover trial. End points were measured from a daily diary that reflected the weekly hive score, the weekly itch score, and a visual analog scale (VAS) score. Secondary to a carryover effect, the first period results were analyzed as a parallel design that compared placebo with dapsone directly by using repeated-measures analysis. Results: After 6 weeks, the patients in the dapsone arm showed mean improvement over baseline in VAS (2.3 [95% CI, 0.6-4.1], P= .01), urticaria score (-3.5 [95% CI, -6.2 to -0.9], P= .01), and itch score (-4.8 [95% CI, -7.6 to -2.1], P= .001), whereas the placebo arm showed no improvement over baseline for VAS, urticaria, or itch scores. Dapsone showed greater improvement compared with placebo for itch (P= .047) and VAS (P= .04). Of the 22 patients, 3 showed complete resolution of hives and itch with dapsone, whereas 31% and 41% had ≥50% resolution of hives and itch, respectively. No serious adverse effects were observed with dapsone. Conclusion: To our knowledge, this is the first double-blind, placebo controlled study of dapsone in CIU and indicates that dapsone has efficacy in patients with antihistamine refractory CIU.

KW - Antihistamine

KW - Chronic idiopathic urticaria

KW - Dapsone

KW - RCT

KW - Urticaria

UR - http://www.scopus.com/inward/record.url?scp=84925108209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925108209&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2014.06.004

DO - 10.1016/j.jaip.2014.06.004

M3 - Article

VL - 2

SP - 601

EP - 606

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

IS - 5

ER -